Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
HKEX’s Permissive IPO Rules Could Open Opportunities for Korea to Strengthen Its Position in International Listings 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
GSK just fired Moncef Slaoui from his post as Galvani Bioelectronics board chairman this week. The executive also served as the chief scientist for the U.S. government’s Operation Warp Speed, a coronavirus vaccine development group under Donald Trump’s administration.
CNBC reported that GlaxoSmithKline terminated Slaoui due to sexual harassment claims that were raised by a woman who was not named. His dismissal was announced by GSK on March 24.
The alleged offenses that led to Slaoui’s dismissal
Slaoui was a scientist and board chair at Galvani Bioelectronics, where GSK is a major shareholder. This is why it was GlaxoSmithKline that made the decision to get rid of him.
Moreover, it was revealed that in February, GSK received a letter that described Slaoui’s sexual harassment offenses and other misconducts committed toward the company’s employees. Based on the allegations, Dr. Slaoui’s inappropriate conduct happened several years ago when he was still working directly for GlaxoSmithKline.
After the concerns have been raised over the former board chairman’s behavior, GSK acted swiftly and axed the erring executive. His dismissal is effective immediately. At any rate, Slaoui lost his job 10 months after Trump appointed him to manage the country’s effort to develop COVID-19 vaccines.
“Dr. Slaoui's behaviors are wholly unacceptable,” GSK stated via a press release that was posted on March 24. “They represent an abuse of his leadership position, violate company policies, and are contrary to the strong values that define GSK's culture.”
It was added that everyone at GSK is expected to behave in accordance with the company’s values, especially its leaders. The firm then stressed that sexual harassment and other abuse of leadership are not tolerated and strictly prohibited.
About Moncef Slaoui
The fired Moncef Slaoui is 61 years old now and has been with GSK for 30 years. His wife, Kristen Slaoui, was a former GSK’s vice president and head of business development in the past.
When he was assigned as the chief advisor of Operation Warp Speed, he was a board member at Moderna pharmaceuticals. Due to criticisms for his connection to Moderna, while being an official at OWS, he resigned from the board of Moderna and sold his shares. However, Slaoui refused to give up his shares in GSK and said that those are his “retirement plan.”
